Copolymeric Micelles Overcome the Oral Delivery Challenges of Amphotericin B

Abstract

Classified as a Biopharmaceutical Classification System (BCS) class IV drug, amphotericin B (AmB) has low aqueous solubility and low permeability leading to low oral bioavailability. To improve these limitations, this study investigated the potential of AmB-loaded polymeric micelles (AmB-PM) to increase intestinal absorption. AmB-PM were prepared with polyvinyl caprolactam–polyvinyl acetate–polyethylene glycol copolymer (Soluplus®) as a polymeric carrier and used a modified solvent diffusion and microfluidics (NanoAssemblr®) method. AmB-PM have a mean particle size of ~80 nm and are mono-disperse with a polydispersity index <0.2. The entrapment efficiency of AmB was up to 95% and achieved with a high drug loading up to ~20% (w/w) with a total amount of incorporated drug of 1.08 ± 0.01 mg/mL. Importantly, compared to free drug, AmB-PM protected AmB from degradation in an acidic (simulated gastric) environment. Viability studies in Caco-2 cells confirmed the safety/low toxicity of AmB-PM. In vitro cellular absorption studies confirmed that AmB-PM increased AmB uptake in Caco-2 cells 6-fold more than free AmB (i.e., 25% compared with 4% within 30 min). Furthermore, the permeability of AmB across Caco-2 monolayers was significantly faster (2-fold) and more pronounced for AmB-PM in comparison to free drug (3.5-fold increase). Thus, the developed AmB-PM show promise as a novel oral delivery system for AmB and justifies further investigation.

Effectiveness of fluconazole as antifungal prophylaxis in cancer patients undergoing chemotherapy, radiotherapy, or immunotherapy: systematic review and meta‐analysis

“…In this sense, amphotericin B presents seven of those ligations and is more active against fungi than nystatin, being possible to use the parenteral route for its administration [12]. In contrast, amphotericin B is poorly absorbed when administered orally, as performed in the primary studies of this review, which could justify the reduced effectiveness of the compound [54].…”

Recent progress of magnetic nanoparticles in biomedical applications: A review

“…The recent progress in the field of nanoscaled drugs/gene carriers such as micelles, [ 120,121 ] liposomes, [ 122,123 ] hydrogels, [ 124 ] dendrimers, [ 125 ] and mesoporous silica nanoparticles [ 126 ] is phenomenal. Still, these nanocarrier suffers from some challenges such as off‐targeting accumulation of carriers, [ 127 ] low penetration through blood brain barrier (BBB), [ 125 ] low circulating time in blood, [ 122 ] low physical and chemical stability, [ 123 ] premature release of cargo molecules [ 128 ] and low drug loading efficacy.…”

Recent Bio-medical applications of iron oxide magnetic nanoparticles

“…Furthermore, when IOMNPs are employed as nano-transporters, the toxicity of the drug may be altered as a concern of an adjustment of its bio dispersal. For these motives, an in-depth assessment of the cell toxicity is hence required for each case about the planned solicitation [57][58][59][60][61][62] .…”